Heard on the Street: The Trump administration’s ambition to unleash biomedical innovation and sharpen America’s edge against China is colliding with a far messier reality inside the FDA

9 hours ago 2
Unexpected delays, infighting and a staffing situation are fueling investors’ unease.
Read Entire Article